Petros Pharmaceuticals Inc (PTPI) - Net Assets
Based on the latest financial reports, Petros Pharmaceuticals Inc (PTPI) has net assets worth $-9.58 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.61 Million) and total liabilities ($27.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Petros Pharmaceuticals Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-9.58 Million |
| % of Total Assets | -54.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | -142.75% |
| 10-Year Change | N/A |
| Growth Volatility | 103.47 |
Petros Pharmaceuticals Inc - Net Assets Trend (2018–2024)
This chart illustrates how Petros Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see PTPI company net worth.
Annual Net Assets for Petros Pharmaceuticals Inc (2018–2024)
The table below shows the annual net assets of Petros Pharmaceuticals Inc from 2018 to 2024. Also explore net asset growth rate of Petros Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-7.47 Million | -159.84% |
| 2023-12-31 | $12.48 Million | -25.28% |
| 2022-12-31 | $16.70 Million | -53.01% |
| 2021-12-31 | $35.54 Million | +103.47% |
| 2020-12-31 | $17.47 Million | +117.84% |
| 2019-12-31 | $8.02 Million | +576.97% |
| 2018-12-31 | $-1.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Petros Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11152710200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.05K | % |
| Other Components | $105.74 Million | % |
| Total Equity | $-7.47 Million | 100.00% |
Petros Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Petros Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BOOSH PLANT-BASED BRANDS
F:77I
|
$101.47K |
|
Xtract Resources PLC
LSE:XTR
|
$101.59K |
|
Headlam Group
LSE:HEAD
|
$102.56K |
|
Titon Holdings Plc
LSE:TON
|
$102.65K |
|
Sensys Traffic AB
ST:SENS
|
$99.20K |
|
TAURUS GOLD CORP.
F:W1N
|
$98.90K |
|
Safestay PLC
LSE:SSTY
|
$98.76K |
|
OCA Acquisition Corp
NASDAQ:OCAXU
|
$98.52K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Petros Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,480,023 to -7,467,578, a change of -19,947,601 (-159.8%).
- Net loss of 14,318,790 reduced equity.
- Dividend payments of 1,292,916,000 reduced retained earnings.
- Share repurchases of 6,234,087 reduced equity.
- Other comprehensive income increased equity by 408,982,000.
- Other factors increased equity by 884,539,276.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.32 Million | -191.75% |
| Dividends Paid | $1.29 Billion | -17313.73% |
| Share Repurchases | $6.23 Million | -83.48% |
| Other Comprehensive Income | $408.98 Million | +5476.77% |
| Other Changes | $884.54 Million | +11845.06% |
| Total Change | $- | -159.84% |
Book Value vs Market Value Analysis
This analysis compares Petros Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-16.81 | $0.05 | x |
| 2019-12-31 | $32.60 | $0.05 | x |
| 2020-12-31 | $32.71 | $0.05 | x |
| 2021-12-31 | $32.64 | $0.05 | x |
| 2022-12-31 | $8.07 | $0.05 | x |
| 2023-12-31 | $5.74 | $0.05 | x |
| 2024-12-31 | $-0.93 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Petros Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -280.10%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-110.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -231.10% | 0.21x | 0.00x | $-32.30 Million |
| 2019 | -405.42% | -208.71% | 0.27x | 7.28x | $-33.31 Million |
| 2020 | -117.84% | -215.35% | 0.14x | 4.00x | $-22.33 Million |
| 2021 | -26.32% | -119.77% | 0.12x | 1.90x | $-12.91 Million |
| 2022 | -161.88% | -451.22% | 0.18x | 1.94x | $-28.71 Million |
| 2023 | -65.41% | -140.20% | 0.17x | 2.71x | $-9.41 Million |
| 2024 | 0.00% | -280.10% | 0.48x | 0.00x | $-13.57 Million |
Industry Comparison
This section compares Petros Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $139,729,099
- Average return on equity (ROE) among peers: -14.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Petros Pharmaceuticals Inc (PTPI) | $-9.58 Million | 0.00% | N/A | $101.47K |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $-185.83 Million | 0.00% | 0.00x | $133.55 Million |
| Akanda Corp (AKAN) | $26.90 Million | -43.34% | 0.45x | $1.51 Million |
| Akebia Ther (AKBA) | $-30.58 Million | 0.00% | 0.00x | $245.86 Million |
| Alkermes Plc (ALKS) | $305.31 Million | 42.74% | 1.15x | $7.73 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.58 Billion |
| Amphastar P (AMPH) | $364.36 Million | -1.57% | 0.41x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $61.30 Million | -137.01% | 55.65x | $5.96 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $108.93 Million | 10.79% | 0.30x | $278.90 Million |
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.